Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report:

01. NICE’s response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Ferring Pharmaceuticals

03. Consultee comments on the ACD - British Association of Urological Surgeons

04. Consultee comments on the ACD - British Uro-Oncology Group

05. Consultee comments on the ACD - Tackle Prostate Cancer (formerly Prostate Cancer Support Federation)

06. Consultee comments on the ACD - Prostate Cancer UK

07. Commentator comments on the ACD - National Collaborating Centre for Cancer

08. Patient expert comments on the ACD - Watson

09. Public comments on the ACD received via the NICE website

10. Additional evidence - Ferring Pharmaceuticals

10. Critique of additional evidence - School of Health and Related Research (ScHARR)

11. Article by Albertson et al from European Urology